Cargando…
Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)
Ibrutinib is an inhibitor of Bruton's tyrosine kinase that has been approved for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom's macroglobulinemia and is connected with toxicities. To minimize its toxicities, we linked ibrutinib to a cell...
Autores principales: | Faust, Andreas, Bäumer, Nicole, Schlütermann, Alina, Becht, Manuel, Greune, Lilo, Geyer, Christiane, Rüter, Christian, Margeta, Renato, Wittmann, Lisa, Dersch, Petra, Lenz, Georg, Berdel, Wolfgang E., Bäumer, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299256/ https://www.ncbi.nlm.nih.gov/pubmed/34725904 http://dx.doi.org/10.1002/anie.202109769 |
Ejemplares similares
-
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
por: Bäumer, Nicole, et al.
Publicado: (2022) -
Targeted siRNA nanocarrier: a platform technology for cancer treatment
por: Bäumer, Nicole, et al.
Publicado: (2022) -
CsMgPO(4)
por: Strutynska, Nataliya Yu., et al.
Publicado: (2009) -
Cs(2)Bi(PO(4))(WO(4))
por: Terebilenko, Kateryna V., et al.
Publicado: (2009) -
Post-operative AICS status in completely resected lung cancer patients with pre-operative AICS abnormalities: predictive significance of disease recurrence
por: Anayama, Takashi, et al.
Publicado: (2018)